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The “new kids on the block”, although 
now not so “new”, include the sodium/glu-
cose cotransporter-2 (SGLT-2) inhibitors, 
dipeptidyl peptidase IV (DPP-IV) inhibi-
tors, and glucagon-like peptide 1 receptor 
agonists (GLP-1 RA).
Recent cardiovascular outcome trials 
(CVOTs) have demonstrated benefits of 
SGLT-2 inhibitors in decreasing hospi-
talization for heart failure in populations 
with and without existing cardiovascular 
disease (CVD), with less consistent effects 
on other outcomes such as cardiovascular 
(CV) death. The EMPA-REG study [2] 
was the first of these studies to be presented. 
It demonstrated that, in a population with 
established CVD, those randomized to em-
pagliflozin had a decreased risk of CV death. 
The CANVAS [3] and DECLARETIMI 
[4] studies included populations with and 
without established CVD, the former show-
ing superiority of the drug on MACE out-
comes (major adverse cardiovascular events, 
a composite of death, myocardial infarction, 
or repeat coronary revascularization of the 
target lesion), whilst the latter study dem-
onstrated that the use of dapagliflozin was 
non-inferior for MACE outcomes and de-
creased the risk of renal disease, a feature 
also of the use of SGLT-2 inhibitors in the 
other two studies.
These CV and renal benefits were the first 
seen for any class of oral anti-hyperglycemic 
agents. However, these benefits or “ups” need 
to be balanced with potential side effects.
The last decade has seen a rise in the 
number of new classes of non-insulin anti-
hyperglycemic pharmacological therapies 
for type 2 diabetes, following a dearth of 
pharmacological developments. The “ups” 
include the ability of physicians to have an 
ever growing armamentarium of medica-
tions to use. However, coincident with this 
increase comes about confusion as to which 
medications might be most suitable for a 
particular patient. This confusion might be 
better described as the agony of choice, an 
inadvertent “down”.
All anti-hyperglycemic medications 
lower glucose levels and glycated hemoglo-
bin (HbA1c) to variable degrees, a feature 
necessary for regulatory approval. What is 
recognized now is that the way in which 
these medications may achieve the HbA1c 
improvements as well as their non-glycemic 
effects are important, particularly cardiovas-
cular safety.
Also important to consider is that a sig-
nificant proportion of those living with dia-
betes may be from countries where cost of 
the newer medications may be prohibitive 
for a number of reasons. It is fortuitous that 
the updated American Diabetes Association 
(ADA)/European Association for the Study 
of Diabetes (EASD) guidelines (2018) [1] 
recognize this large subgroup of patients, 
in addition to emphasizing the need for 
patient-centered care, education and en-
gagement of the patient as well as health 
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lished topline results of the REWIND study 
(dulaglutide) indicate CV benefits in those 
receiving dulaglutide. The other benefits of 
this class are that weight loss can occur to-
gether with improvements in blood pressure 
and other metabolic parameters. However, 
ways in which to predict who will respond 
best remain elusive and emphasize the need 
always to individualize therapy.
The “old dogs” such as metformin, sulpho-
nylureas, and thiazolidinediones (TZDs) 
cannot be forgotten as these are often either 
prescribed as first-line medications (metfor-
min) or are affordable in many parts of the 
world in comparison to the newer agents 
and, as such, are the only medications which 
are available for use in these countries. Sul-
phonylureas are potent glucose-lowering 
agents, but carry an increased risk of hy-
poglycemia compared with all other non-
insulin agents. The results of the CAROLI-
NA study, in which linagliptin is compared 
with glimeperide, will be presented at the 
American Diabetes Association Scientific 
Sessions in 2019 and will potentially pro-
vide important data regarding the safety of 
sulphonylureas.
The CV safety of pioglitazone was demon-
strated in the PROactive study [13]. How-
ever, this drug class is associated with weight 
gain, which many patients do not consider 
favorable, as well as an increased risk of heart 
failure when combined with insulin [14]. 
Nevertheless, when used in low dose early in 
combination with metformin and exenatide, 
the authors of the EDICT study have dem-
onstrated sustained effects on HbA1c with 
low rates of hypoglycaemia [15].
One can see from the above that the 
prescriber now has a variety of classes of 
medications to choose from; or an “agony of 
choice”. Each class has its “ups and downs” 
and there may be within class differences, 
particularly when considering the newer 
agents. Guidelines are important, but the 
medication choice ultimately results from 
the physician and patient interaction. Ev-
ery “up” and “down” influences the choice 
of pharmacotherapy, and published benefits 
such as weight loss may not be perceived by 
some patients as an advantage. CVOTs and 
registration studies indicate to the physician 
what can happen (good and bad) over the 
defined length of the study. However, what 
eludes us at this time is how to determine 
in which person a drug will be effective or 
ineffective, hence the need for personalized 
medicine.
These include the well-known risk of my-
cotic genitourinary infections, hypotension 
and increased urination, as well as a rarer 
but recognized association with a new en-
tity of euglycemic diabetic ketoacidosis [5]. 
A tantalizing signal of increased lower limb 
amputations and small bone fractures was 
also seen in the CANVAS study [3]. These 
similarities and differences have sparked 
considerable debate as to whether there are 
within class differences which might account 
for these disparities and whether differences 
in SGLT-1 and SGLT-2 receptor affinity are 
relevant [6]. However, it should always be 
noted that studies involved different popu-
lations and that direct comparisons may be 
fraught with limitations. However, these 
“downs” seem to be relatively small in com-
parison with the “ups” which include CV as 
well as renal benefits. Nevertheless, the phy-
sician will need to be familiar with these po-
tential side effects, to have a checklist when 
prescribing and to ensure that these side 
effects and precautions are explained to the 
patient. The results of dedicated studies in 
renal impairment such as CREDENCE as 
well as those addressing heart failure specifi-
cally including EMPEROR-Preserved and 
EMPEROR-Reduced will strengthen our 
knowledge of where and when these drugs 
might fit in [7].
The DPP IV inhibitors seem to be overall 
neutral in their effects of CV risk, although 
there was an unexplained increase in hospi-
talizations for heart failure in those subjects 
taking the active drug in the SAVOR-TIMI 
study [8]. However, overall these medica-
tions appear to be moderate in their poten-
tial glucose-lowering effects and in general 
safe and simple to prescribe, particularly 
when combined with metformin, especially 
in the older patient. In some cases, dose 
reductions need to be made where there is 
renal dysfunction.
There are a variety of GLP-1 RA which 
can be divided into short-acting, where daily 
or twice daily administration is required, to 
longer-acting agents, which can be adminis-
tered daily to weekly. Longer-acting agents, 
which may be able to be given monthly or 
even 6 monthly, are in development. Results 
of the LEADER [9] and SUSTAIN-6 [10] 
study indicate potential CV benefits of li-
raglutide and semaglutide when adminis-
tered to a population at high risk of CVD 
whilst others have been non-inferior for CV 
outcomes (ELIXA—lixisenatide and EXS-
CEL—bydureon) [11,12]. The yet unpub-
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